Why targeted use of desiccants and scavengers matters:

Desiccants and oxygen scavengers serve as protective packaging tools to mitigate moisture and oxygen ingress. However, their use should not be default or precautionary. Instead, their inclusion must be based on actual stability study outcomes or forced degradation data indicating sensitivity to humidity or oxidation. Inappropriate use can increase cost, complicate packaging validation, and introduce regulatory scrutiny.

Risks of unjustified inclusion:

Using these components without supporting data may trigger regulatory questions, delay submissions, or result in costly post-approval changes. Overuse can also interfere with product performance (e.g., affecting moisture content or reaction kinetics) or require unnecessary label statements. Regulators expect a risk-based justification for all primary packaging decisions.

Regulatory and Technical Context:

Guidance from ICH and global regulators:

ICH Q1A(R2) and WHO TRS 1010 mandate that packaging design be justified based on data demonstrating its ability to protect the product over its intended shelf life. FDA and EMA also expect applicants to provide evidence (e.g., impurity trends, assay loss, visual changes) to support the need for moisture or oxygen protection. The justification must be clearly documented in CTD Module 3.2.P.7 (Container Closure) and 3.2.P.8.1 (Stability Summary).

Audit expectations and submission review:

During inspections or dossier evaluations, regulators may question why a desiccant or scavenger is included. If no clear correlation exists between environmental sensitivity and product degradation, the packaging may be seen as excessive or misleading. Reviewers also assess whether inclusion was supported by degradation studies or stress tests.

Best Practices and Implementation:

Use data-driven assessments to decide inclusion:

Conduct real-time and accelerated stability studies across conditions such as 25°C/60% RH, 30°C/75% RH, and 40°C/75% RH. Evaluate whether the product shows sensitivity to moisture (e.g., dissolution delay, hydrolysis, discoloration) or oxygen (e.g., peroxide growth, color fade, assay drop). If no significant degradation is observed, avoid using additional protection. Reserve desiccant or scavenger inclusion for molecules or formulations that clearly show environmental vulnerability.

Document rationale in protocols and submissions:

Clearly state in your stability protocol whether desiccants or oxygen scavengers are used during testing. If they are part of the final marketed packaging, include comparative studies showing results with and without these components. Present this data in CTD Module 3.2.P.2.5 (Development Pharmaceutics) and reference findings in the stability justification section.

If used for only certain markets (e.g., Zone IVB), define which conditions trigger their inclusion and how performance was validated.

Control and validate their performance over shelf life:

Desiccants and scavengers themselves must be evaluated over the full product shelf life. Confirm that their capacity remains effective at the end of the study and does not leach contaminants. Include compatibility studies with product formulation, container closure materials, and label adhesives. Reference vendor certificates, qualification tests, and in-house validation in packaging dossiers.

Monitor their presence during pull points and include inspection criteria in your SOPs to ensure consistent inclusion and performance in commercial batches.

Why temperature excursion control is essential:

Temperature excursions—temporary deviations from defined storage conditions—can affect a drug product’s stability and efficacy. Not all products respond the same way to temperature stress, so applying generic limits is scientifically unsound and regulatory risky. Instead, limits should be based on the product’s physicochemical properties, degradation profile, formulation sensitivity, and packaging characteristics.

Consequences of applying blanket excursion thresholds:

Using arbitrary limits (e.g., ±2°C for 24 hours) without product-specific justification may result in overlooked degradation or unnecessary product rejection. Regulatory authorities expect manufacturers to defend excursion allowances with data. Failure to do so can lead to warning letters, import bans, or shelf-life reductions following inspection or post-market complaints.

Regulatory and Technical Context:

ICH and WHO guidance on risk-based excursion management:

ICH Q1A(R2) emphasizes evaluating storage conditions relevant to the product’s intended distribution and lifecycle. WHO TRS 1010 requires defining temperature excursion allowances based on actual degradation behavior. Regulators across the US, EU, and APAC regions expect documented risk assessments, supporting stability data, and excursion protocols aligned to product performance and sensitivity.

What inspectors and auditors expect to see:

Auditors typically review the scientific rationale used to set temperature thresholds in transport SOPs, distribution agreements, and excursion management policies. They may cross-check these values against real-time and accelerated stability data. Any discrepancies—such as wider commercial limits than those supported by data—may result in observations or require post-approval data supplementation.

Best Practices and Implementation:

Conduct product-specific risk assessments:

Perform a risk assessment based on:

• API degradation kinetics (e.g., hydrolysis, oxidation)
• Formulation type (e.g., biologic, suspension, lipid-based)
• Container closure system and moisture sensitivity
• Intended storage conditions (e.g., refrigerated, ambient)

Use stress testing, accelerated stability data, and historical excursion studies to define short-term excursion limits (e.g., 30°C for 24 hours) that will not impact quality attributes.

Integrate excursion thresholds into procedures and labels:

Include product-specific excursion tolerances in SOPs, stability protocols, and shipment validation plans. Define acceptable duration, maximum and minimum temperatures, and corrective actions. For cold chain products, clarify upper and lower thresholds, and validate packaging to simulate thermal excursions.

Consider including statements like “Excursions up to 30°C for 48 hours are acceptable” in the package insert if supported by data.

Document, monitor, and act on excursions proactively:

Train distribution partners and QA teams on monitoring temperature logs and flagging deviations. Use electronic data loggers to track shipments and auto-flag out-of-limit exposures. If excursions exceed defined thresholds, initiate a CAPA and conduct a scientific impact assessment before releasing the batch.

Maintain excursion records and risk justifications for audit readiness and regulatory submissions. Periodically reassess excursion tolerances as new data emerges or formulation changes occur.